FREE SHIPPING ON ORDERS OVER £60 (UK)

AT THE FOREFRONT OF BIOTECHNOLOGICAL INNOVATION IN PRODUCTS BASED ON 100% PURE MUSHROOMS

At Hifas da Terra, we are committed to innovation and scientific research, offering premium quality supplements and conducting preclinical and clinical trials, as well as other scientific studies.

Through this approach, we are expanding beyond biotechnology into biopharma, developing new patentable product categories and next-generation medical devices.

Key data on R&D

We allocate 62% of our profits to R&D

More than 200 experts work with us. We collaborate with various medical and scientific entities.

We have a wide scientific team and more than 200 multidisciplinary collaborators. Some of the entities we collaborate are:

More than 15 active projects

We are the Biotech Leader in Research and Development of Innovative Supplements, with more than 15 active studieswhich include clinical trials highly innovative linked to projects Micromarker and Microimmunomama. Likewise, other studies of great interest in other fundamental areas stand out.

Scientific and Biotechnological Innovation

Through innovation, we propose new processes and responsible protocols that positively impact people ...

We innovate in organic mushroom cultivation by introducing sustainable production in bioreactors, a pioneering system that allows mycelium to be cultivated under standardised conditions and expands the medical applications of extracts by varying culture media, selecting specific strains geared towards results, etc. This system also allows us to more effectively isolate active biomolecules and new ingredients for our nutritional supplements.

We are laying the groundwork for what we call our “catered formula”, innovative, targeted formulations designed to address specific needs, situations, and conditions. At Hifas da Terra, we are currently conducting clinical studies on our products, alongside research focused on optimising our production processes to ensure even greater efficacy and consistency.

The expertise acquired through the scientific and technological knowledge of our R&D&I team opens the door to the creation of new patents based on mushrooms, whether in the form of food supplements or medical devices, among others.

We at Hifas da Terra always stride to innovate so we always actively take part or initiate studies involving medicinal mushrooms

Micromarker

Micromarker

2021 – 2024
  • Home 2021
  • Clinical essay in colorectal cancer
  • Patients: 144
  • Medical Center: Galicia Sur Biomedical Foundation
Microimmunomama

Microimmunomama

2021 – 2024
  • Home 2021
  • Clinical test in breast cancer
  • Patients: +100
  • Medical Center: Álvaro Cunqueiro Hospital
AI-VIDDA

AI-VIDDA

RIS3 2021–2027
  • AI and biotechnology in older people to increase years of healthy life.
New disruptive ingredients

New disruptive ingredients

PERTE 2023–2025
  • Sustainable alternatives in the agri -food sector (AcceleREat - Agrifood belong).
Nutrigen 4.0

Nutrigen 4.0

2021 – 2024
  • Intelligent processes with edible mushrooms from Galicia.
Covid-19 study in residences

Covid-19 study in residences

2020
  • Observational study with COVID-19 patients and mushroom extracts.
  • Patients: 76
  • Medical Center: Leganés / Dr. Soler
Mico-Artro

Mico-Artro

2018
  • Relief of osteoarthritis symptoms with fungi.
  • Patients: 20
  • Medical Center: OAFI / Dr. Moller
Neurofood

Neurofood

2018 – 2021
  • Human essay on mushrooms effects in memory and cognition.
  • Patients: 40
  • Medical Center: Foltra / Dr. Devesa Center
FungitechOnco

FungitechOnco

2019 – 2021
  • Medicinal mushroom for gastric and colorectal cancer prevention.
Dismetasine

Dismetasine

2018 – 2021
  • Mico-Mix and Metabolic Syndrome. Santiago Hospital / Dr. Casanueva.
  • Patients: 44